141 related articles for article (PubMed ID: 25451544)
1. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation.
Wohl BM; Smith AA; Jensen BE; Zelikin AN
J Control Release; 2014 Dec; 196():197-207. PubMed ID: 25451544
[TBL] [Abstract][Full Text] [Related]
2. Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs.
Wohl BM; Smith AA; Kryger MB; Zelikin AN
Biomacromolecules; 2013 Nov; 14(11):3916-26. PubMed ID: 24156371
[TBL] [Abstract][Full Text] [Related]
3. Macromolecular Prodrugs of Ribavirin: Structure-Function Correlation as Inhibitors of Influenza Infectivity.
Riber CF; Hinton TM; Gajda P; Zuwala K; Tolstrup M; Stewart C; Zelikin AN
Mol Pharm; 2017 Jan; 14(1):234-241. PubMed ID: 28043136
[TBL] [Abstract][Full Text] [Related]
4. Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells.
Ruiz-Sanchis P; Wohl BM; Smith AA; Zuwala K; Melchjorsen J; Tolstrup M; Zelikin AN
Adv Healthc Mater; 2015 Jan; 4(1):65-8. PubMed ID: 25132665
[TBL] [Abstract][Full Text] [Related]
5. Macromolecular prodrugs for controlled delivery of ribavirin.
Kryger MB; Smith AA; Wohl BM; Zelikin AN
Macromol Biosci; 2014 Feb; 14(2):173-85. PubMed ID: 24105953
[TBL] [Abstract][Full Text] [Related]
6. Macromolecular prodrugs of ribavirin: concerted efforts of the carrier and the drug.
Smith AA; Wohl BM; Kryger MB; Hedemann N; Guerrero-Sanchez C; Postma A; Zelikin AN
Adv Healthc Mater; 2014 Sep; 3(9):1404-7. PubMed ID: 24408515
[TBL] [Abstract][Full Text] [Related]
7. Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug.
Kryger MB; Wohl BM; Smith AA; Zelikin AN
Chem Commun (Camb); 2013 Apr; 49(26):2643-5. PubMed ID: 23431562
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
9. Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity.
Hinton TM; Zuwala K; Deffrasnes C; Todd S; Shi S; Marsh GA; Dearnley M; Wohl BM; Tolstrup M; Zelikin AN
Adv Healthc Mater; 2016 Mar; 5(5):534-40. PubMed ID: 26789641
[TBL] [Abstract][Full Text] [Related]
10. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
Meppen M; Pacini B; Bazzo R; Koch U; Leone JF; Koeplinger KA; Rowley M; Altamura S; Di Marco A; Fiore F; Giuliano C; Gonzalez-Paz O; Laufer R; Pucci V; Narjes F; Gardelli C
Eur J Med Chem; 2009 Sep; 44(9):3765-70. PubMed ID: 19493593
[TBL] [Abstract][Full Text] [Related]
11. Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.
Koutsoudakis G; Romero-Brey I; Berger C; Pérez-Vilaró G; Monteiro Perin P; Vondran FW; Kalesse M; Harmrolfs K; Müller R; Martinez JP; Pietschmann T; Bartenschlager R; Brönstrup M; Meyerhans A; Díez J
J Hepatol; 2015 Oct; 63(4):813-21. PubMed ID: 26070407
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hepatitis C virus replication by chalepin and pseudane IX isolated from Ruta angustifolia leaves.
Wahyuni TS; Widyawaruyanti A; Lusida MI; Fuad A; Soetjipto ; Fuchino H; Kawahara N; Hayashi Y; Aoki C; Hotta H
Fitoterapia; 2014 Dec; 99():276-83. PubMed ID: 25454460
[TBL] [Abstract][Full Text] [Related]
13. Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
Gardelli C; Attenni B; Donghi M; Meppen M; Pacini B; Harper S; Di Marco A; Fiore F; Giuliano C; Pucci V; Laufer R; Gennari N; Marcucci I; Leone JF; Olsen DB; MacCoss M; Rowley M; Narjes F
J Med Chem; 2009 Sep; 52(17):5394-407. PubMed ID: 19725579
[TBL] [Abstract][Full Text] [Related]
14. Cyclic monophosphate prodrugs of base-modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication.
Gunic E; Girardet JL; Ramasamy K; Stoisavljevic-Petkov V; Chow S; Yeh LT; Hamatake RK; Raney A; Hong Z
Bioorg Med Chem Lett; 2007 May; 17(9):2452-5. PubMed ID: 17331721
[TBL] [Abstract][Full Text] [Related]
15. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
16. Nucleotide prodrugs for the treatment of HCV infection.
Sofia MJ
Adv Pharmacol; 2013; 67():39-73. PubMed ID: 23885998
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C replication inhibitors that target the viral NS4B protein.
Miller JF; Chong PY; Shotwell JB; Catalano JG; Tai VW; Fang J; Banka AL; Roberts CD; Youngman M; Zhang H; Xiong Z; Mathis A; Pouliot JJ; Hamatake RK; Price DJ; Seal JW; Stroup LL; Creech KL; Carballo LH; Todd D; Spaltenstein A; Furst S; Hong Z; Peat AJ
J Med Chem; 2014 Mar; 57(5):2107-20. PubMed ID: 23544424
[TBL] [Abstract][Full Text] [Related]
18. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
[TBL] [Abstract][Full Text] [Related]
19. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of a new phosphorylated ribavirin prodrug.
Dong SD; Lin CC; Schroeder M
Antiviral Res; 2013 Jul; 99(1):18-26. PubMed ID: 23624267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
